http://www.acc.org/Feed?clinicalTopicID=b042e697-0209-4f33-95ea-10f0eede0dad Clinical Topic Feed: Primary Hyperlipidemia en /Latest-in-Cardiology/Articles/2026/03/18/00/50/eagles-eye-view-18mar2025 In this week’s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. 1773842400000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/13/15/20/ACC-AHA-Release-New-Clinical-Guideline-For-Managing-Dyslipidemia The new ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive “one-stop shop” for addressing the evaluation, management and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a) (Lp[a]). 1773415860000 Articles and Stories /Latest-in-Cardiology/Articles/2025/11/06/13/19/JACC-Journals-Publish-Latest-Science-From-aha-2025 AHA 2025 features key science simultaneously published across ACC's JACC Journals, including JACC, JACC: CardioOncology, JACC: Advances, JACC: Case Reports, JACC: Heart Failure and JACC: Cardiovascular Imaging. 1762527600000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2025/11/05/14/44/Study-Finds-Routine-Genetic-Screening Routine screening of newborns for familial hypercholesterolemia (FH) is feasible with first-tier biochemical testing followed by reflex second-tier genetic testing, according to a cross-sectional study published Oct. 29 in JAMA Cardiology. 1762353900000 Articles and Stories /Latest-in-Cardiology/Articles/2025/01/29/17/15/eagles-eye-view-29jan2025 In this week’s View, Dr. Eagle examines the cost-effectiveness of polypills. He then discusses overweight and obesity in patients with familial hyperlipidemia. 1738171020000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2025/01/21/22/07/Overweight-Obesity Overweight and obesity are common in patients with heterozygous familial hypercholesterolemia (HeFH) and are associated with a greater risk of atherosclerotic cardiovascular disease (ASCVD) starting in childhood and regardless of LDL-C level and lipid-lowering medication, according to a cross-sectional analysis published Jan. 13 in the European Heart Journal. 1737499440000 Articles and Stories /Latest-in-Cardiology/Articles/2024/11/13/21/17/mon-314pm-combo-lipid-aha-2024 Advances in lipid therapeutics were the focus of a late-breaking science session at AHA 2024, with researchers presenting findings evaluating the safety of the novel new drug muvalaplin in lowering high levels of lipoprotein(a) [Lp(a)]... 1731960840000 Articles and Stories /Education-and-Meetings/Patient-Case-Quizzes/2024/01/08/19/20/To-Swim-or-Not-to-Swim A 32-year-old male competitive swimmer with probable familial hyperlipidemia (with a Dutch Lipid Clinic Network score [DLCNS] of 6 points) presents with exertional chest pain. 1705928400000 Educational Activities /Latest-in-Cardiology/Journal-Scans/2024/01/16/04/08/familial-hypercholesterolemia-in What are the characteristics of children and adolescents with heterozygous familial hypercholesterolemia (HeFH) that may assist in the identification and management of familial hypercholesterolemia (FH)? 1705409880000 Articles and Stories /Latest-in-Cardiology/Articles/2023/07/12/13/43/eagles-eye-view-12jul2023 In this week’s View, Dr. Eagle explores a JACC State-of-the-Art Review of consumer wearable health and fitness technology and its role in cardiovascular medicine. He then discusses the 2023 update of the European Atherosclerosis Society’s consensus statement on homozygous familial hypercholesterolemia that offers new treatments and clinical guidance. 1689177600000 Articles and Stories